Answers are grounded in this paper and cite their sources.
Policy changes may limit negotiations on high-cost drugs in Medicare, suggesting potential higher spending ahead.
Part B drugs will be negotiated for the first time in IPAY 2028. Policy changes, such as the OBBBA, exclude several high-cost products from negotiation. These policy decisions have major implications for how the Drug Price Negotiation Program targets high-spend drugs and achieves meaningful savings for the Medicare program.
No takes yet. Share an insight, caveat, or question.
Cousin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: